T1	Participants 825 839	1,323 patients
T2	Participants 631 782	localized prostate cancer with an elevated prostate-specific antigen (PSA) < or = 100 ng/mL and an estimated risk of lymph node (LN) involvement of 15%
T3	Participants 889 898	WP + NCHT
T4	Participants 900 909	PO + NCHT
T5	Participants 911 919	WP + AHT
T6	Participants 924 932	PO + AHT
